免疫检查点抑制剂单药或联合化疗在ERBB2突变NSCLC中的疗效
该回顾性研究基于德国国家基因组医学肺癌联盟数据,评估ERBB2突变NSCLC患者接受免疫检查点抑制剂(ICI)单药或联合化疗的疗效。一线ICI联合化疗患者ORR为52%、中位PFS 6个月、1年OS率88%;二线及以上ICI单药ORR为16%、中位PFS 4个月、中位OS 10个月。结论认为ICI单药及联合铂双药化疗均有效,可能作为当前标准治疗及靶向治疗的基准。
要点
- 一线ICI联合化疗在ERBB2突变NSCLC中ORR达52%,中位PFS 6个月,1年OS率88%。
- 二线及以上ICI单药ORR为16%,中位PFS 4个月,中位OS 10个月。
- ICI单药及联合铂双药化疗均显示疗效,或可成为靶向治疗的疗效基准。
核心结论
- ICI单药及联合铂双药化疗在ERBB2突变NSCLC中均有效,可能作为当前标准治疗及靶向治疗的基准。
研究设计与样本
- 回顾性研究,基于德国国家基因组医学肺癌联盟,评估ERBB2突变NSCLC患者接受ICI单药或联合化疗的疗效。
- 一线ICI联合化疗或单药治疗27例,二线及以上ICI单药治疗34例。
主要发现
- 一线ICI联合化疗患者ORR为52%,中位PFS为6个月,1年OS率为88%。
- 二线及以上ICI单药患者ORR为16%,中位PFS为4个月,中位OS为10个月。
临床怎么用
- ERBB2突变NSCLC可考虑ICI联合铂双药化疗作为一线治疗选择。
- 后线可考虑ICI单药治疗,但需结合患者具体情况评估获益。
局限性
- 回顾性研究设计,样本量有限,一线联合治疗仅27例。
- 缺乏与靶向治疗的直接对照数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In contrast to other driver mutations, no targeted therapies have yet been approved in ERBB2-mutated NSCLC (HER2mu NSCLC). Nevertheless, several compounds have revealed promising early efficacy data, which need to be evaluated in the context of current standard approaches. Although data on the efficacy of immune checkpoint inhibitors (ICIs) in second or subsequent lines of treatment remain limited and conflicting, there are virtually no data on patient outcome under ICI/platinum-doublet combinations in the first-line setting. METHODS: We retrospectively evaluated outcomes of patients with HER2mu NSCLC treated with ICI alone or in combination with chemotherapy within the German National Network Genomic Medicine Lung Cancer consortium by means of overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). RESULTS: ICI either in combination with chemotherapy or as monotherapy was applied as first-line treatment in 27 patients, whereas 34 received single-agent ICI in second or subsequent lines. Patient characteristics were in line with previously published data. In treatment-naive patients receiving ICI in combination with chemotherapy, the ORR, median PFS, and OS rate at 1 year were 52%, 6 months, and 88%, respectively. In second or subsequent lines, ICI monotherapy was associated with an ORR of 16%, a median PFS of 4 months, and a median OS of 10 months. CONCLUSIONS: ICIs are effective as monotherapy and in combination with platinum-doublet chemotherapy. Therefore, ICI-based treatments may be found as the current standard of care and benchmark for targeted therapies in HER2mu NSCLC.
引用
- Saalfeld FC, Wenzel C, Christopoulos P, et al. Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations. J Thorac Oncol. 2021. PMID: 34245914. doi:10.1016/j.jtho.2021.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。